Ensuring drug-crystal formation

Engineers at Leeds University have developed a simple technology that can be used in existing chemical reactors to ensure ‘right first time’ drug-crystal formation.

Engineers at Leeds University have developed a simple technology that can be used in existing chemical reactors to ensure ‘right first time’ drug-crystal formation.

Ensuring drug crystals are formed correctly is crucial to their efficacy and the efficiency of pharmaceutical manufacturers’ operations.

‘We’ve shown that we can produce a well-defined crystal structure using a self-assembled monolayer bound onto a metal substrate within a regular reactor. This is exciting stuff, because it’s a relatively simple system but could make a huge difference in the efficiency of drug manufacture,’ said Prof Kevin Roberts of the university’s Faculty of Engineering.

One of the first stages of the crystallisation process is called nucleation. During nucleation, particles are introduced into a reactor to encourage the formation of crystals. However, the way in which this is currently carried out is difficult to control and can often lead to the wrong shape, size or structure of drug crystal, something that affects the usefulness and efficacy of the compound.

Register now to continue reading

Thanks for visiting The Engineer. You’ve now reached your monthly limit of news stories. Register for free to unlock unlimited access to all of our news coverage, as well as premium content including opinion, in-depth features and special reports.  

Benefits of registering

  • In-depth insights and coverage of key emerging trends

  • Unrestricted access to special reports throughout the year

  • Daily technology news delivered straight to your inbox